Legend Biotech Co. (NASDAQ:LEGN - Free Report) - William Blair dropped their Q1 2025 earnings estimates for shares of Legend Biotech in a report released on Wednesday, March 12th. William Blair analyst S. Corwin now anticipates that the company will post earnings of ($0.40) per share for the quarter, down from their previous estimate of ($0.19). The consensus estimate for Legend Biotech's current full-year earnings is ($1.31) per share. William Blair also issued estimates for Legend Biotech's Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.85) EPS, Q1 2026 earnings at $0.03 EPS, Q2 2026 earnings at $0.16 EPS, Q3 2026 earnings at $0.26 EPS, Q4 2026 earnings at $0.33 EPS and FY2026 earnings at $0.79 EPS.
Other analysts have also recently issued reports about the stock. HC Wainwright boosted their price objective on shares of Legend Biotech from $73.00 to $75.00 and gave the company a "buy" rating in a research note on Wednesday, March 12th. Guggenheim restated a "neutral" rating on shares of Legend Biotech in a report on Wednesday, March 12th. Royal Bank of Canada restated an "outperform" rating and set a $86.00 target price on shares of Legend Biotech in a report on Monday, December 9th. Morgan Stanley reduced their target price on shares of Legend Biotech from $82.00 to $80.00 and set an "overweight" rating on the stock in a report on Monday. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $83.00 target price on shares of Legend Biotech in a report on Monday, December 9th. One analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, Legend Biotech presently has a consensus rating of "Moderate Buy" and an average price target of $79.00.
Check Out Our Latest Stock Report on Legend Biotech
Legend Biotech Trading Down 1.6 %
Shares of NASDAQ LEGN traded down $0.60 during trading on Monday, hitting $37.49. 373,157 shares of the company traded hands, compared to its average volume of 1,163,399. Legend Biotech has a 1 year low of $30.17 and a 1 year high of $62.78. The company has a 50-day moving average price of $35.94 and a 200-day moving average price of $40.45. The firm has a market capitalization of $6.85 billion, a P/E ratio of -39.36 and a beta of 0.19. The company has a quick ratio of 4.90, a current ratio of 4.98 and a debt-to-equity ratio of 0.27.
Legend Biotech (NASDAQ:LEGN - Get Free Report) last released its earnings results on Tuesday, March 11th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of ($0.39) by $0.46. Legend Biotech had a negative net margin of 66.92% and a negative return on equity of 29.69%. The firm had revenue of $186.50 million during the quarter, compared to analysts' expectations of $179.00 million. During the same period in the previous year, the company earned ($0.40) EPS. Legend Biotech's revenue for the quarter was up 134.6% on a year-over-year basis.
Institutional Investors Weigh In On Legend Biotech
A number of institutional investors have recently modified their holdings of the stock. Lansforsakringar Fondforvaltning AB publ acquired a new stake in shares of Legend Biotech in the 4th quarter valued at about $914,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Legend Biotech during the 4th quarter valued at about $776,000. Polar Asset Management Partners Inc. grew its position in shares of Legend Biotech by 65.8% during the 4th quarter. Polar Asset Management Partners Inc. now owns 24,638 shares of the company's stock valued at $802,000 after buying an additional 9,779 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Legend Biotech during the 4th quarter valued at about $56,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Legend Biotech by 36.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 136,438 shares of the company's stock valued at $4,440,000 after buying an additional 36,181 shares during the last quarter. Institutional investors and hedge funds own 70.89% of the company's stock.
About Legend Biotech
(
Get Free Report)
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).
Featured Stories
Before you consider Legend Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Legend Biotech wasn't on the list.
While Legend Biotech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
